ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 171 filers reported holding ASCENDIS PHARMA A/S in Q4 2021. The put-call ratio across all filers is 1.59 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $37,619,853 | -12.7% | 350,866 | -0.6% | 3.56% | -29.5% |
| Q4 2022 | $43,088,441 | -16.1% | 352,808 | -29.1% | 5.06% | -26.1% |
| Q3 2022 | $51,356,000 | +27.8% | 497,347 | +15.1% | 6.85% | -14.5% |
| Q2 2022 | $40,175,000 | +6.4% | 432,170 | +34.4% | 8.01% | -19.7% |
| Q1 2022 | $37,745,000 | +28.6% | 321,621 | +47.4% | 9.98% | +19.1% |
| Q4 2021 | $29,349,000 | – | 218,158 | – | 8.38% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 2,003,147 | $225,574,000 | 20.44% |
| RA Capital Management | 4,914,955 | $553,473,000 | 17.48% |
| Sofinnova Investments, Inc. | 1,109,874 | $124,983,000 | 11.56% |
| Eversept Partners, LP | 275,494 | $31,023,379 | 7.71% |
| Avoro Capital Advisors LLC | 1,787,000 | $201,234,000 | 6.79% |
| Orbimed Advisors | 3,287,400 | $370,194,000 | 6.22% |
| Eventide Asset Management | 1,698,648 | $191,285,000 | 6.19% |
| Logos Global Management LP | 120,000 | $13,513,000 | 5.14% |
| Ghost Tree Capital, LLC | 150,000 | $16,892,000 | 4.48% |
| Spyglass Capital Management LLC | 351,388 | $39,570,000 | 4.47% |